CLL specialist Ryan Jacobs, M.D., from Levine Cancer Institute, shared findings with HealthTree at the EHA 2024 conference about the outcomes of the fixed-duration treatment combination ibrutinib and venetoclax for patients with high-risk CLL. Watch his interview or read the summary below.
Ibrutinib (Imbruvica, Janssen Biotech) and venetoclax (Venclexta, AbbVie) are FDA-approved targeted therapies for CLL, both given as pills. In countries like Europe and Canada, the medicines are approved for CLL patients as a fixed-duration treatment combination. In the United States, these medicines are FDA-approved as individual treatments, not yet in combination.
In the phase 2 CAPTIVATE study, CLL patients received ibrutinib and venetoclax for a little over 1 year and then stopped. Four years after stopping treatment, follow-up data showed:
With the encouraging findings, Dr. Jacobs hopes a fixed-duration treatment combination of venetoclax and a BTK inhibitor like ibrutinib will become available to CLL patients in the U.S. soon. Click here to learn more about fixed-duration vs. continuous-duration CLL therapies.
We invite you to click the button below to subscribe to our newsletter and stay updated on the latest advancements in chronic lymphocytic leukemia.
JOIN THE HEALTHTREE FOR CLL NEWSLETTER
Source:
CLL specialist Ryan Jacobs, M.D., from Levine Cancer Institute, shared findings with HealthTree at the EHA 2024 conference about the outcomes of the fixed-duration treatment combination ibrutinib and venetoclax for patients with high-risk CLL. Watch his interview or read the summary below.
Ibrutinib (Imbruvica, Janssen Biotech) and venetoclax (Venclexta, AbbVie) are FDA-approved targeted therapies for CLL, both given as pills. In countries like Europe and Canada, the medicines are approved for CLL patients as a fixed-duration treatment combination. In the United States, these medicines are FDA-approved as individual treatments, not yet in combination.
In the phase 2 CAPTIVATE study, CLL patients received ibrutinib and venetoclax for a little over 1 year and then stopped. Four years after stopping treatment, follow-up data showed:
With the encouraging findings, Dr. Jacobs hopes a fixed-duration treatment combination of venetoclax and a BTK inhibitor like ibrutinib will become available to CLL patients in the U.S. soon. Click here to learn more about fixed-duration vs. continuous-duration CLL therapies.
We invite you to click the button below to subscribe to our newsletter and stay updated on the latest advancements in chronic lymphocytic leukemia.
JOIN THE HEALTHTREE FOR CLL NEWSLETTER
Source:
about the author
Megan Heaps
Megan joined HealthTree in 2022. As a writer and the daughter of a blood cancer patient, she is dedicated to helping patients and their caregivers understand the various aspects of their disease. This understanding enables them to better advocate for themselves and improve their treatment outcomes. In her spare time, she enjoys spending time with her family.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.